Literature DB >> 30069822

123I-meta-Iodobenzylguanidine Imaging in Patients with Cardiac Resynchronization Therapy: Results are Intriguing, but Unknowns Remain.

Anisiia Doytchinova1, Myron C Gerson2.   

Abstract

Entities:  

Year:  2018        PMID： 30069822     DOI： 10.1007/s12350-018-1381-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  19 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis.

Authors:  Derk O Verschure; Caroline E Veltman; Alain Manrique; G Aernout Somsen; Maria Koutelou; Athanasios Katsikis; Denis Agostini; Myron C Gerson; Berthe L F van Eck-Smit; Arthur J H A Scholte; Arnold F Jacobson; Hein J Verberne
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-03-30       Impact factor: 6.875

Review 3.  Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan.

Authors:  Kenichi Nakajima; Tomoaki Nakata
Journal:  J Nucl Med       Date:  2015-06       Impact factor: 10.057

4.  Reliability of the 123I-mIBG heart/mediastinum ratio: Results of a multicenter test-retest reproducibility study.

Authors:  Timothy M Bateman; Karthikeyan Ananthasubramaniam; Daniel S Berman; Myron Gerson; Robert Gropler; Milena Henzlova; Fernando Mendoza; Michael Miyamoto; Mahesh Shah; Frederick Weiland
Journal:  J Nucl Cardiol       Date:  2018-01-17       Impact factor: 5.952

5.  Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines.

Authors:  Camilla Normand; Cecilia Linde; Jagmeet Singh; Kenneth Dickstein
Journal:  JACC Heart Fail       Date:  2018-04       Impact factor: 12.035

6.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.

Authors:  P Merlet; H Valette; J L Dubois-Randé; D Moyse; D Duboc; P Dove; M H Bourguignon; C Benvenuti; A M Duval; D Agostini
Journal:  J Nucl Med       Date:  1992-04       Impact factor: 10.057

7.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.

Authors:  Arnold F Jacobson; Roxy Senior; Manuel D Cerqueira; Nathan D Wong; Gregory S Thomas; Victor A Lopez; Denis Agostini; Fred Weiland; Harish Chandna; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2010-02-25       Impact factor: 24.094

Review 8.  Cardiac sympathetic nervous system imaging with 123I-meta-iodobenzylguanidine: Perspectives from Japan and Europe.

Authors:  Kenichi Nakajima; Arthur J H A Scholte; Tomoaki Nakata; Aukelien C Dimitriu-Leen; Taishiro Chikamori; João V Vitola; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2017-03-13       Impact factor: 5.952

9.  Myocardial imaging with a radioiodinated norepinephrine storage analog.

Authors:  D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes
Journal:  J Nucl Med       Date:  1981-01       Impact factor: 10.057

10.  Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models.

Authors:  Kenichi Nakajima; Tomoaki Nakata; Shinro Matsuo; Arnold F Jacobson
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-12-24       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.